Evidence map›Paper›PMID 37667175›Full record

ArticleBMC bioinformatics2023

Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma.

Evgueni Jacob, Angélique Perrillat-Mercerot, Jean-Louis Palgen, Adèle L'Hostis, Nicoletta Ceres, Jean-Pierre Boissel, Jim Bosley, Claudio Monteiro, Riad Kahoul

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Evgueni JacobNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France. evgueni.jacob@novadiscovery.com.
Angélique Perrillat-MercerotNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Jean-Louis PalgenNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Adèle L'HostisNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Nicoletta CeresNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Jean-Pierre BoisselNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Jim BosleyNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Claudio MonteiroNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Riad KahoulNovadiscovery, 1 Place Giovanni Da Verrazzano, 69009, Lyon, France.
Novant Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the past several decades, metrics have been defined to assess the quality of various types of models and to compare their performance depending on their capacity to explain the variance found in real-life data. However, available validation methods are mostly designed for statistical regressions rather than for mechanistic models. To our knowledge, in the latter case, there are no consensus standards, for instance for the validation of predictions against real-world data given the variability and uncertainty of the data. In this work, we focus on the prediction of time-to-event curves using as an application example a mechanistic model of non-small cell lung cancer. We designed four empirical methods to assess both model performance and reliability of predictions: two methods based on bootstrapped versions of parametric statistical tests: log-rank and combined weighted log-ranks (MaxCombo); and two methods based on bootstrapped prediction intervals, referred to here as raw coverage and the juncture metric. We also introduced the notion of observation time uncertainty to take into consideration the real life delay between the moment when an event happens, and the moment when it is observed and reported.

resultsWe highlight the advantages and disadvantages of these methods according to their application context. We have shown that the context of use of the model has an impact on the model validation process. Thanks to the use of several validation metrics we have highlighted the limit of the model to predict the evolution of the disease in the whole population of mutations at the same time, and that it was more efficient with specific predictions in the target mutation populations. The choice and use of a single metric could have led to an erroneous validation of the model and its context of use.

conclusionsWith this work, we stress the importance of making judicious choices for a metric, and how using a combination of metrics could be more relevant, with the objective of validating a given model and its predictions within a specific context of use. We also show how the reliability of the results depends both on the metric and on the statistical comparisons, and that the conditions of application and the type of available information need to be taken into account to choose the best validation strategy.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsHumansReproducibility of ResultsUncertaintyEGFR protein, humanErbB ReceptorsBootstrapConfidence intervalCoverageEGFR + lung adenocarcinomaEmpiricalJonctureKnowledge based modelLog-rankMechanistic modelPrediction intervalValidation

Identifiers

PMID37667175
PMCPMC10478282
OpenAlexW4386423115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.